Related Experiment Videos
Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use
1Department of Physiology & Pharmacology and The Ivey Chair in Molecular Toxicology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada. pmadadi@uwo.ca
Pharmacogenomics
|September 11, 2008
Summary
Codeine, used for pain and cough, shows variable effectiveness in children due to genetic factors and developmental changes. Further research is needed to ensure safe and effective pediatric use of this common medication.
Area of Science:
- Pharmacology
- Genetics
- Pediatrics
Background:
- Codeine has been a common analgesic and antitussive since the 1800s.
- Its use in pediatric populations and breastfeeding mothers is widespread despite limited safety data.
- Variability in codeine efficacy has long been observed, with recent research exploring genetic underpinnings.
Purpose of the Study:
- To review the factors influencing codeine efficacy and safety in pediatric patients.
- To highlight the role of pharmacogenomics in understanding inter-individual variability in codeine response.
- To emphasize the importance of developmental factors in pediatric drug metabolism.
Main Methods:
- Literature review of studies on codeine use in children.
- Analysis of genetic factors affecting drug-metabolizing enzymes, receptors, and transporters.
- Consideration of the developing blood-brain barrier and enzyme ontogeny in neonates and young children.
Main Results:
- Genetic variability in key enzymes significantly impacts codeine metabolism and efficacy.
- The maturation of drug-metabolizing enzymes and the blood-brain barrier influences drug response in pediatric patients.
- Limited empirical data exists on the safety of codeine in the pediatric age group.
Conclusions:
- Understanding pharmacogenomic variations is crucial for optimizing codeine therapy in children.
- Developmental factors in newborns and young children necessitate careful consideration when prescribing codeine.
- Further methodic studies are required to establish evidence-based guidelines for pediatric codeine use.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...